Evidence map›Paper›PMID 37308561›Full record

ArticleScientific reports2023

Impact of COVID-19 prevention and control on tuberculosis and scarlet fever in China's Guizhou.

Jian Zhou, Hui-Juan Chen, Ting-Jia Lu, Pu Chen, Yan Zhuang, Jin-Lan Li

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jian ZhouGuizhou Center for Disease Control and Prevention, Institute for Tuberculosis Prevention and Control, Guizhou, 550004, China.
Hui-Juan ChenGuizhou Center for Disease Control and Prevention, Institute for Tuberculosis Prevention and Control, Guizhou, 550004, China.
Ting-Jia LuHaixiao Street Community Health Service Center, Guizhou, 563200, China.
Pu ChenGuizhou Center for Disease Control and Prevention, Institute for Tuberculosis Prevention and Control, Guizhou, 550004, China.
Yan ZhuangGuizhou Center for Disease Control and Prevention, Institute for Tuberculosis Prevention and Control, Guizhou, 550004, China.
Jin-Lan LiGuizhou Center for Disease Control and Prevention, Institute for Tuberculosis Prevention and Control, Guizhou, 550004, China. lijinlanpublic@126.com.
Guizhou Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

China has implemented a series of long-term measures to control the spread of COVID-19, however, the effects of these measures on other chronic and acute respiratory infectious diseases remain unclear. Tuberculosis (TB) and scarlet fever (SF) serve as representatives of chronic and acute respiratory infectious diseases, respectively. In China's Guizhou province, an area with a high prevalence of TB and SF, approximately 40,000 TB cases and hundreds of SF cases are reported annually. To assess the impact of COVID-19 prevention and control on TB and SF in Guizhou, the exponential smoothing method was employed to establish a prediction model for analyzing the influence of COVID-19 prevention and control on the number of TB and SF cases. Additionally, spatial aggregation analysis was utilized to describe spatial changes in TB and SF before and after the COVID-19 outbreak. The parameters of the TB and SF prediction models are R

Indexed as

Communicable DiseasesCOVID-19Scarlet FeverTuberculosisChinaHumans

Identifiers

PMID37308561
PMCPMC10258764
OpenAlexW4380370695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.